Treatment of glioblastoma

Treatment of malignant neoplasms is one of the unsolved problems of modern medical science. This becomes especially relevant when brain tumors. In the general structure of malignant neoplasms, primary brain tumors account for 2%. The most common (more than 10 times) are metastatic tumors, which develop in 20-25% of cancer patients, with the most common sources of metastasis being lung, breast, kidney, colorectal cancer, melanoma and others. The total number of patients with malignant brain tumors in Russia is 70-80 thousand people per year. Characterized by a hidden, asymptomatic and very aggressive course and a wide polymorphism of clinical manifestations, they create significant difficulties and errors in diagnosing the disease.

Treatment of brain tumors is one of the most difficult problems in oncology. Even radical treatment does not guarantee the development of local relapse and progression of the process, especially with glioblastoma, as with other tumors. When performing an operation, it is often impossible to remove the entire tumor; the possibilities of chemotherapy are limited by the difficulties of penetration of many drugs through the blood-brain barrier, and radiation and radiosurgical methods are limited by the development of adverse radiation reactions and complications. The failures of chemo-radiation treatment methods are also explained by the low sensitivity (chemo- and radio-resistance) of brain tumors to these treatment methods. That is why many patients are content with only palliative and symptomatic treatment measures aimed only at temporary relief of pain and suffering.

Among the newest and very promising methods of treating advanced and complicated malignant diseases of the brain is the approach widely used in the OncoCare 308 Clinic using genetically engineered drugs based on TNF and IFN gamma. These drugs have been registered and used in the Russian Federation for more than 10 years. 2 drugs are used, the duration of 1 course of therapy is 20 days; to realize the effect of treatment, we recommend 3-6 courses of therapy.


The main goal of the method is to launch mechanisms in the body to heal itself. It helps stimulate the body's cytotoxic defense against the tumor, increasing the body's resistance and destroying cancer cells.


Together with the cells of the immune system, TNF promptly identifies cancer cells and starts the process of their destruction by cells of the immune system. With a genetic mutation in TNF308, the body produces insufficient amounts of cytokines that can block the development and growth of cancer cells. Therefore, when exogenous TNF-T cytokines (TNF Thymosin alpha1) are introduced into the body, they immediately combine with endogenous cytokines secreted by the body itself and have an enhanced effect on cancer cells, blocking the development of cancer at the gene level. That is, by increasing the level of TNF, we help the body stop the development of cancer and promote its regression.

The method can be used at any stage of antitumor treatment, including in patients who have exhausted all other treatment options. Good tolerability, ease of use, as well as the ability to combine it with any other methods of therapy in oncology make it the method of choice for advanced stages of cancer, not only of the brain, but also of other localizations - melanoma, lung, kidney, bladder, gastrointestinal -intestinal tract, etc.

As an example indicating the high effectiveness of the method, we present an extract from the patient’s medical history.

Patient B.M., 45 years old. In June 2021, a mass formation was detected in the left parietal lobe of the brain. The patient was operated on and microsurgical removal of the tumor in the left parietal lobe was performed. Histological conclusion - Glioblastoma Grade IV. Radiation therapy was performed using a linear accelerator SOD 60 Gy, after which he received a course of temozolomide chemotherapy for 28 days. A follow-up examination (MRI) revealed progression of the process – continued growth of the tumor. In October 2021, he was re-operated - tumor removal followed by polychemo (bevacizumab + irinotecan, 3 injections). Progression and continued growth were noted.
04.10. applied to OncoCare Clinic 308. Cytokinogenetic therapy was recommended, 3-6 courses, program 1. 3 courses of therapy were administered with intervals between courses of 10 days. He endured the treatment quite satisfactorily; there were no reactions or complications during the treatment process, with the exception of an increase in body temperature to 38.5-39.0 degrees. It was not observed for 2-3 days. At the end of the third course, a follow-up examination (PET/CT on 01/28/23 and MRI on 12/19/22 and 01/23/23) did not reveal any evidence of relapse of the disease. She feels good, has no complaints, quality of life is ECOG 1, works in her main specialty.
Cytokinogenetic therapy is currently ongoing.

This report demonstrates the possibility of cytokinogenetic therapy to provide effective control in aggressive malignant brain tumors.